Accelerating Microbiome
Innovation

The BioCollective has built the most comprehensive platform to develop innovative microbiome therapeutics: to Collect better samples, Connect high quality data, and Correct our most urgent health conditions.

 
new_banner_lab.jpg
 

PARTNERS

 

main_group.jpg

To understand how this early-stage company has won awards for science and innovation while winning customers like Janssen, Mosaic, and Harvard,
you have to think differently.

 
 
 

The microbiome is the hottest frontier in biotech, with major pharma, technology, food, and academic organizations racing to find a model for creating new health solutions. We have developed tools for microbiome innovation that can be applied across the entire spectrum of health.

 
microscope_new_1800.jpg
 

COLLECT | Kits, Samples
& Collection Services

Quality samples are critical for more robust data analysis and discovery.  

The BioCollector Kit™ is a patented system for simplified, collection of quality, standardized, whole stool samples. Used by customers like Harvard’s Dana-Farber Cancer Insitute, The University of Chicago, and AXIAL Biotherapeutics. Our ick-free system captures high-quality samples of the whole stool. With BioCollector™ any research is instantly comparable and repeatable for multi-omic analysis — from genomics to metabolomics to isolation and culturing.

col_samp.jpg
samples_2.jpg
 
 

"Old models won't work when it comes to the microbiome. We are tapping into some of the leading microbiome knowledge, creating new categories and leading new ways of advancing toward microbiome-based therapeutics."

  • Martha Carlin, CEO

 
bigPic_bg.jpg

CONNECT | Data & Sample Bank

The BioCollective is unlocking the microbiome with unprecedented depth and scope. Through our bank of population samples across age, health, disease, lifestyle, and environmental factors. Through microbial metadata, The BioCollective platform discovers and analyzes patterns that others might miss. This has helped us rapidly discover biomarkers, culture microbes, improve strain characterization, and build a world-class strain bank — all of which help us develop functional probiotic therapeutics and other applications.

Read: CSO Dr. Raul Cano - Publications

caribou.jpg
 
data_bg.jpg

CORRECT | Our Health Innovation Platform

The combination of our expertise in individual domains and material access [clarify this] have allowed us to create an end-to-end testing and development platform — a comprehensive ecosystem for microbiome research.

Our data, strain library, formulation systems, and BioFlux™ Metabolic Model provide a path for product development across pharma, food, home care products, and more.  BioFlux’s in silico analysis of microbial community dynamics within the gut microbiome offers actionable insights for novel probiotic formulation.

Read Dr. Naseer Sangwan’s research on microbial ecology

Learn how BioFlux is accelerating product
development, including The BioCollective’s debut formulation
Sugar Buster Biotica.

 
 
 
data_blk_bg.jpg
 

" What the BioCollective has accomplished is breathtaking: they are pushing the boundaries of science and sequencing to make connections that will change food and healthcare for the better. ”

Linda Avey / Co-Founder 23 and Me

 
 
dna_deconstruct.jpg
 
 

Reference Materials

Leveraging our expertise in whole stool collection, homogenization and processing we are working with NIST to improve industry standards, The BioCollective has developed a line of products to serve as reference materials for research.

 
 
ref_home_bg_2.jpg
 
pink_sugarB.jpg

CORRECT | Probiotics

Sugar Buster Biotica is scientifically designed to restore function and balance.  Through The BioCollective’s rapid advancements in complex modeling, metagenomic sequencing and extensive probiotic strain library scientifically designed and validated formulations are now within reach.

Sugar Buster Biotica is available now

 
 

The Vision

When Martha Carlin’s husband John was diagnosed with early-onset Parkinson’s Disease in 2002, she had no time to wait and hope for a cure. She began engaging with researchers and experts – and everything she found pointed to the gut microbiome, the ‘invisible organ’ that’s sometimes called the second brain. Martha knew she had to pull together a team that knew how to think differently, and The BioCollective was born. Since then, the BioCollective team have been driving to unleash the power of the microbiome through industry-leading methods. The team has developed ways to easily Collect samples; to harness new metagenomic data and proprietary software to Connect patterns that emerge; and to produce a novel probiotic (with more in the pipeline) to Correct balance in the gut.

And 16 years later, John is beating the odds, boxing, cycling, ice-climbing, and leading Parkinson’s support groups. The BioCollective is here to help others the way it has helped John.

View : Martha at TEDx Boulder & The White House

 
 
 

Nature | June ‘18

“Before we can make correlations of microorganisms with a condition, we need to know that the microbiome we have is reflective of reality.”

Dr. Raul Cano

Nature / Read Full Article

 

PubMed | May ‘18

American Gut: an Open Platform for Citizen Science Microbiome Research.

Dr. Naseer Sangwan

PubMed / Read Full Article

 

Tomorrow Edition | Dec ‘17

Our gut is our internal pharmacy where food and drinks are transformed into vitamins, hormones, neurotransmitters and enzymes.  In order for us to be healthy we must restore the function and balance of this vital organ.

CEO Martha Carlin

Tomorrow Edition / Read Full Article

 

Microbiome Times | Sep ‘18

I understood Parkinson’s as a systemic problem; these are systemic conditions and require that same systems approach from my business career to fully understand what’s going on. So I started applying my systems thinking to the problem.

CEO Martha Carlin

MicrobiomeTimes / Read Full Article

 
 

The Team

Martha Carlin Founder & Chief Executive Revolutionary

Martha Carlin
Founder & Chief Executive Revolutionary

Dr. Raul Cano, PhD Chief Scientific Officer   Publications

Dr. Raul Cano, PhD
Chief Scientific Officer
Publications

Dr. Naseer Sangwan, PhD Director of Bioinformatics   Publications

Dr. Naseer Sangwan, PhD
Director of Bioinformatics
Publications

 
 
Co-Founder Dr. Jack Gilbert   Publications

Co-Founder
Dr. Jack Gilbert
Publications

 
Co-Founder Dr. Suzanne Vernon   Publications

Co-Founder
Dr. Suzanne Vernon
Publications

 

Advisors

Linda Avey  Co-Founder, 23andme

Linda Avey
Co-Founder, 23andme

Alan Lewis  Dir of Govt Affairs, Natural Grocers

Alan Lewis
Dir of Govt Affairs, Natural Grocers

Noah Voreades   Principal, Genbiome Consulting

Noah Voreades
Principal, Genbiome Consulting

Jaroslav Boublik  CSO, Activated Nutrients, LeafCann

Jaroslav Boublik
CSO, Activated Nutrients, LeafCann

Tom Aarts  Nutrition Business Advisors

Tom Aarts
Nutrition Business Advisors

Ceci Zak  COO , Batten Co Omnicom Sanofi

Ceci Zak
COO , Batten Co
Omnicom Sanofi

Steve Kazemi  CEO, Pure Cultures Ops, Nutraceutics

Steve Kazemi
CEO, Pure Cultures
Ops, Nutraceutics

Rita Colwell  Former Dir of NSF Founder, CosmosID

Rita Colwell
Former Dir of NSF
Founder, CosmosID